Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89

L Allott; C Da Pieve; J Meyers; T Spinks; D M Ciobota; G Kramer-Marek; G Smith

doi:10.1039/c7cc03572a

Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89

Chem Commun (Camb). 2017 Jul 27;53(61):8529-8532. doi: 10.1039/c7cc03572a.

Authors

L Allott¹, C Da Pieve¹, J Meyers², T Spinks¹, D M Ciobota¹, G Kramer-Marek¹, G Smith¹

Affiliations

¹ Division of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, UK. graham.smith@icr.ac.uk.
² Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 123 Old Brompton Road, London, UK.

Abstract

The future of ⁸⁹Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO). Herein, we report the evaluation of the octadentate molecule DFO-HOPO (3) as a suitable chelator for ⁸⁹Zr and a more stable alternative to DFO. The molecule showed good potential for the future development of a DFO-HOPO-based bifunctional chelator (BFC) for the radiolabelling of biomolecules with ⁸⁹Zr. This work broadens the selection of available chelators for ⁸⁹Zr in search of improved successors to DFO for clinical ⁸⁹Zr-immuno-PET.

Abstract

Grants and funding